ArticleACS omega2026
Multiomics Integration Reveals Yu-Xue-Bi Tablets Attenuate Rheumatoid Arthritis via Metabolic Reprogramming-Mediated Piezo1 Suppression.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a systemic chronic inflammatory disease, Rheumatoid arthritis (RA) is characterized by progressive inflammation and bone and cartilage destruction, leading to significant disability, reduced lifespan, and increased mortality. The clinical use of conventional medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and corticosteroids, is associated with significant adverse effects. Long-term administration may induce various toxicities, such as hepatotoxicity, nephrotoxicity, osteoporosis, and heightened infection susceptibility. While newer biological agents demonstrate improved efficacy, they may elevate risks of serious infections and malignancies. Additionally, a subset of patients exhibit inadequate response to these biologic therapies. Given the limitations of current therapies, identifying safer and more effective therapeutic targets and strategies for RA is imperative. Here, we report the efficacy of Yu-Xue-Bi Tablets (YXB), a classic traditional Chinese medicine (TCM) formula, in treating RA. YXB-treated collagen-induced arthritis (CIA) mice exhibited improved general health with markedly ameliorated joint integrity and local inflammation. Mechanistically, RNA-seq analysis of synovial tissue revealed that YXB exerts therapeutic effects in RA by suppressing the mechanosensitive ion channel Piezo1. Integrated metabolomic and transcriptomic analyses suggested that YXB ameliorates metabolic disorders in CIA mice, leading to Piezo1 downregulation, a finding validated in primary macrophages. Collectively, our findings demonstrate that YXB alleviates RA by suppressing Piezo1 expression via metabolic reprogramming, offering a novel therapeutic strategy for the clinical treatment of RA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.